Table 2.

Multivariate predictive models for biochemical and LRFRs

VariableHRP
Entire cohort of 247 patients with prostate cancer, bRFR
 Gleason scorea2.660.015
 PSA1.075<0.001
 HP10b1.0230.019
 HP10 with timec0.99950.001
142 patients with bulkd tumor at the site of the oxygen measurements, bRFR
 Age1.0730.021
 PSA1.085<0.001
 HP10b1.0360.004
 HP10 with timec0.9992<0.001
70 patients with prostate biopsies for local control, LRFR
 HP10b1.0370.043
 HP10 with timec0.99910.032

NOTE: No effect of age, clinical T-category, the proportion of positive diagnostic biopsy cores, radiotherapy dose, or the use of hormonal therapy on either bRFR or LRFR.

  • aGleason 8 versus 6 or 7.

  • bEffect of HP10 on outcome (bRFR or LRFR) at the completion of treatment.

  • cHP10 time dependence. Time expressed in months from the date of the oxygen measurements.

  • dSee text for definition of bulk tumor.